Global RNA Vaccines Market Overview:
Global RNA Vaccines Market is expected to grow at a significant rate during the forecast period 2025-2032, with 2024 as the base year.
Global RNA Vaccines Market Report 2026 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2024-2035, with base year as 2025. This research study of RNA Vaccines involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the RNA Vaccines Market:
The RNA Vaccines Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for RNA Vaccines Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study RNA Vaccines Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, RNA Vaccines market has been segmented into:
Infectious Disease Treatment RNA Vaccine
Infection Prevention RNA Vaccine
By Application, RNA Vaccines market has been segmented into:
Cancer Immunotherapy
Allergy Tolerization
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The RNA Vaccines market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the RNA Vaccines market.
Top Key Players Covered in RNA Vaccines market are:
Argos Therapeutics
Inc.
Arcturus Therapeutics Inc.
BioNTech SE
CureVac AG
Ethris GmbH
GlaxoSmithKline PLC
Moderna Therapeutics Inc.
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: RNA Vaccines Market by Type
4.1 RNA Vaccines Market Snapshot and Growth Engine
4.2 RNA Vaccines Market Overview
4.3 Infectious Disease Treatment RNA Vaccine
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2024-2035F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 Infectious Disease Treatment RNA Vaccine: Geographic Segmentation Analysis
4.4 Infection Prevention RNA Vaccine
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2024-2035F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 Infection Prevention RNA Vaccine: Geographic Segmentation Analysis
Chapter 5: RNA Vaccines Market by Application
5.1 RNA Vaccines Market Snapshot and Growth Engine
5.2 RNA Vaccines Market Overview
5.3 Cancer Immunotherapy
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2024-2035F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Cancer Immunotherapy: Geographic Segmentation Analysis
5.4 Allergy Tolerization
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2024-2035F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Allergy Tolerization: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 RNA Vaccines Market Share by Manufacturer (2023)
6.1.3 Industry BCG Matrix
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 ARGOS THERAPEUTICS
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Role of the Company in the Market
6.2.5 Sustainability and Social Responsibility
6.2.6 Operating Business Segments
6.2.7 Product Portfolio
6.2.8 Business Performance
6.2.9 Key Strategic Moves and Recent Developments
6.2.10 SWOT Analysis
6.3 INC.
6.4 ARCTURUS THERAPEUTICS INC.
6.5 BIONTECH SE
6.6 CUREVAC AG
6.7 ETHRIS GMBH
6.8 GLAXOSMITHKLINE PLC
6.9 MODERNA THERAPEUTICS INC.
Chapter 7: Global RNA Vaccines Market By Region
7.1 Overview
7.2. North America RNA Vaccines Market
7.2.1 Key Market Trends, Growth Factors and Opportunities
7.2.2 Top Key Companies
7.2.3 Historic and Forecasted Market Size by Segments
7.2.4 Historic and Forecasted Market Size By Type
7.2.4.1 Infectious Disease Treatment RNA Vaccine
7.2.4.2 Infection Prevention RNA Vaccine
7.2.5 Historic and Forecasted Market Size By Application
7.2.5.1 Cancer Immunotherapy
7.2.5.2 Allergy Tolerization
7.2.6 Historic and Forecast Market Size by Country
7.2.6.1 US
7.2.6.2 Canada
7.2.6.3 Mexico
7.3. Eastern Europe RNA Vaccines Market
7.3.1 Key Market Trends, Growth Factors and Opportunities
7.3.2 Top Key Companies
7.3.3 Historic and Forecasted Market Size by Segments
7.3.4 Historic and Forecasted Market Size By Type
7.3.4.1 Infectious Disease Treatment RNA Vaccine
7.3.4.2 Infection Prevention RNA Vaccine
7.3.5 Historic and Forecasted Market Size By Application
7.3.5.1 Cancer Immunotherapy
7.3.5.2 Allergy Tolerization
7.3.6 Historic and Forecast Market Size by Country
7.3.6.1 Bulgaria
7.3.6.2 The Czech Republic
7.3.6.3 Hungary
7.3.6.4 Poland
7.3.6.5 Romania
7.3.6.6 Rest of Eastern Europe
7.4. Western Europe RNA Vaccines Market
7.4.1 Key Market Trends, Growth Factors and Opportunities
7.4.2 Top Key Companies
7.4.3 Historic and Forecasted Market Size by Segments
7.4.4 Historic and Forecasted Market Size By Type
7.4.4.1 Infectious Disease Treatment RNA Vaccine
7.4.4.2 Infection Prevention RNA Vaccine
7.4.5 Historic and Forecasted Market Size By Application
7.4.5.1 Cancer Immunotherapy
7.4.5.2 Allergy Tolerization
7.4.6 Historic and Forecast Market Size by Country
7.4.6.1 Germany
7.4.6.2 UK
7.4.6.3 France
7.4.6.4 Netherlands
7.4.6.5 Italy
7.4.6.6 Russia
7.4.6.7 Spain
7.4.6.8 Rest of Western Europe
7.5. Asia Pacific RNA Vaccines Market
7.5.1 Key Market Trends, Growth Factors and Opportunities
7.5.2 Top Key Companies
7.5.3 Historic and Forecasted Market Size by Segments
7.5.4 Historic and Forecasted Market Size By Type
7.5.4.1 Infectious Disease Treatment RNA Vaccine
7.5.4.2 Infection Prevention RNA Vaccine
7.5.5 Historic and Forecasted Market Size By Application
7.5.5.1 Cancer Immunotherapy
7.5.5.2 Allergy Tolerization
7.5.6 Historic and Forecast Market Size by Country
7.5.6.1 China
7.5.6.2 India
7.5.6.3 Japan
7.5.6.4 South Korea
7.5.6.5 Malaysia
7.5.6.6 Thailand
7.5.6.7 Vietnam
7.5.6.8 The Philippines
7.5.6.9 Australia
7.5.6.10 New Zealand
7.5.6.11 Rest of APAC
7.6. Middle East & Africa RNA Vaccines Market
7.6.1 Key Market Trends, Growth Factors and Opportunities
7.6.2 Top Key Companies
7.6.3 Historic and Forecasted Market Size by Segments
7.6.4 Historic and Forecasted Market Size By Type
7.6.4.1 Infectious Disease Treatment RNA Vaccine
7.6.4.2 Infection Prevention RNA Vaccine
7.6.5 Historic and Forecasted Market Size By Application
7.6.5.1 Cancer Immunotherapy
7.6.5.2 Allergy Tolerization
7.6.6 Historic and Forecast Market Size by Country
7.6.6.1 Turkey
7.6.6.2 Bahrain
7.6.6.3 Kuwait
7.6.6.4 Saudi Arabia
7.6.6.5 Qatar
7.6.6.6 UAE
7.6.6.7 Israel
7.6.6.8 South Africa
7.7. South America RNA Vaccines Market
7.7.1 Key Market Trends, Growth Factors and Opportunities
7.7.2 Top Key Companies
7.7.3 Historic and Forecasted Market Size by Segments
7.7.4 Historic and Forecasted Market Size By Type
7.7.4.1 Infectious Disease Treatment RNA Vaccine
7.7.4.2 Infection Prevention RNA Vaccine
7.7.5 Historic and Forecasted Market Size By Application
7.7.5.1 Cancer Immunotherapy
7.7.5.2 Allergy Tolerization
7.7.6 Historic and Forecast Market Size by Country
7.7.6.1 Brazil
7.7.6.2 Argentina
7.7.6.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
RNA Vaccines Scope:
|
Report Data
|
RNA Vaccines Market
|
|
RNA Vaccines Market Size in 2025
|
USD XX million
|
|
RNA Vaccines CAGR 2025 - 2032
|
XX%
|
|
RNA Vaccines Base Year
|
2024
|
|
RNA Vaccines Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Argos Therapeutics, Inc., Arcturus Therapeutics Inc., BioNTech SE, CureVac AG, Ethris GmbH, GlaxoSmithKline PLC, Moderna Therapeutics Inc..
|
|
Key Segments
|
By Type
Infectious Disease Treatment RNA Vaccine
Infection Prevention RNA Vaccine
By Applications
Cancer Immunotherapy
Allergy Tolerization
|
